Clinical trials
Asthma trials in Sweden
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
87 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2002 | 1 |
| 2004 | 4 |
| 2005 | 7 |
| 2006 | 2 |
| 2007 | 5 |
| 2008 | 3 |
| 2009 | 2 |
| 2010 | 5 |
| 2011 | 3 |
| 2012 | 7 |
| 2013 | 2 |
| 2014 | 3 |
| 2015 | 5 |
| 2016 | 6 |
| 2017 | 6 |
| 2018 | 2 |
| 2019 | 3 |
| 2020 | 4 |
| 2021 | 3 |
| 2022 | 1 |
| 2023 | 3 |
| 2024 | 2 |
| 2025 | 2 |
| 2026 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 71 |
| Active, not recruiting | 5 |
| Recruiting | 4 |
| Unknown status | 4 |
| Terminated | 2 |
| Not yet recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| AstraZeneca | 22 |
| GlaxoSmithKline | 14 |
| Karolinska Institutet | 13 |
| Novartis Pharmaceuticals | 4 |
| Sanofi | 4 |
| Airsonett AB | 2 |
| Boehringer Ingelheim | 2 |
| Region Skane | 2 |
| Aerocrine AB | 1 |
| Barbro Dahlen | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Asthma | 87 |
| Pulmonary Disease, Chronic Obstructive | 9 |
| Lung Diseases | 6 |
| Hypersensitivity | 5 |
| Anxiety Disorders | 4 |
| Bronchial Diseases | 4 |
| Disease | 4 |
| Lung Diseases, Obstructive | 4 |
| Pulmonary Eosinophilia | 4 |
| Respiratory Tract Diseases | 4 |
Trials
Showing 1 to 25 of 87. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.